AstraZeneca upbeat on progress with 'Fasenra' and 'Breztri Aerosphere'
28th Aug 2019 07:38
(Sharecast News) - AstraZeneca announced on Wednesday morning that the US Food and Drug Administration (FDA) has granted 'Orphan Drug Designation' to 'Fasenra' (benralizumab), for the treatment of eosinophilic oesophagitis (EoE).
Read moreAstraZeneca upbeat on progress with 'Fasenra' and 'Breztri Aerosphere'
28th Aug 2019 07:38
(Sharecast News) - AstraZeneca announced on Wednesday morning that the US Food and Drug Administration (FDA) has granted 'Orphan Drug Designation' to 'Fasenra' (benralizumab), for the treatment of eosinophilic oesophagitis (EoE).
Read moreAstraZeneca upbeat on progress with 'Fasenra' and 'Breztri Aerosphere'
28th Aug 2019 07:38
(Sharecast News) - AstraZeneca announced on Wednesday morning that the US Food and Drug Administration (FDA) has granted 'Orphan Drug Designation' to 'Fasenra' (benralizumab), for the treatment of eosinophilic oesophagitis (EoE).
Read moreAstraZeneca upbeat on progress with 'Fasenra' and 'Breztri Aerosphere'
28th Aug 2019 07:38
(Sharecast News) - AstraZeneca announced on Wednesday morning that the US Food and Drug Administration (FDA) has granted 'Orphan Drug Designation' to 'Fasenra' (benralizumab), for the treatment of eosinophilic oesophagitis (EoE).
Read moreAstraZeneca granted marketing authorisation for Roxadustat in China
22nd Aug 2019 08:21
(Sharecast News) - Biopharmaceutical company AstraZeneca has received marketing authorisation for Roxadustat in China for the treatment of anaemia caused by chronic kidney disease in non-dialysis-dependent patients.
Read moreAstraZeneca drug fails to improve on chemotherapy in lung cancer trial
21st Aug 2019 07:22
(Sharecast News) - AstraZeneca confirmed on Wednesday that its Imfinzi (durvalumab) treatment for lung and bladder cancer failed to improve upon survival rates registered by chemotherapy treatment in a clinical trial where it was combined with a human monoclonal antibody.
Read moreAstraZeneca upbeat on latest 'Forxiga' trial outcomes
20th Aug 2019 07:27
(Sharecast News) - AstraZeneca announced positive results from its phase 3 'DAPA-HF' trial on Tuesday, which showed that 'Farxiga' (dapagliflozin) met the primary composite endpoint with a statistically-significant and clinically-meaningful reduction of cardiovascular death or worsening of heart failure - defined as hospitalisation or an urgent heart failure visit - compared to placebo.
Read moreAstraZeneca upbeat on progress with Lynparza and Calquence
14th Aug 2019 07:32
(Sharecast News) - AstraZeneca announced positive results from the phase 3 'PAOLA-1' trial in women with advanced ovarian cancer on Wednesday, alongside its partner MSD.
Read moreThursday broker round-up
27th Jun 2019 11:16
(Sharecast News) - Rightmove: UBS downgrades to sell with a target price of 505p.
Read moreAstraZeneca reveals positive overall survival results from Imfinzi trial
27th Jun 2019 08:28
(Sharecast News) - Biopharmaceutical company AstraZeneca revealed some positive overall survival results from its Phase III CASPIAN trial with Imfinzi, a human monoclonal antibody.
Read moreAstraZeneca gets three new drug approvals in Japan
19th Jun 2019 07:29
(Sharecast News) - AstraZeneca announced three new drug approvals in Japan on Wednesday, with the first for 'Breztri Aerosphere' (budesonide/glycopyrronium/ formoterol fumarate) - formerly PT010 - as a triple-combination therapy to relieve symptoms of chronic obstructive pulmonary disease (COPD).
Read moreAstraZeneca secures another European indication for 'Lynparza'
18th Jun 2019 07:28
(Sharecast News) - AstraZeneca and its partner MSD announced on Tuesday that the European Commission (EC) has approved 'Lynparza' (olaparib) as a first-line maintenance treatment for women with BRCA-mutated advanced ovarian cancer.
Read moreAstraZeneca upbeat on latest 'Calquence' trial data
17th Jun 2019 07:24
(Sharecast News) - AstraZeneca announced detailed results from the interim analysis of the phase 3 'ASCEND' trial on Monday, showing Calquence (acalabrutinib) significantly prolonged the time patients lived without disease progression in relapsed or refractory chronic lymphocytic leukaemia (CLL).
Read moreThursday broker round-up
6th Jun 2019 12:40
(Sharecast News) - EI Group: Berenberg downgrades to hold with a target price of 220p.
Read moreAstraZeneca leukaemia drug meets trial end-point
6th Jun 2019 08:34
(Sharecast News) - AstraZeneca said on Thursday its Calquence leukaemia drug had met the primary endpoint of a phase 3 trial and would allow it to file for regulatory approval later this year.
Read more